Skip to main content
Equibles
BIVI logo

BIVI · Biovie Inc. · Metrics

Track BIVI — free

Use BIVI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BIVI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.24 -0.13 (-9.49%) At close · Oct 20
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Although management continues to pursue the Company’s strategic plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”
View the 10-K filed Aug 13, 2026
Market Cap
$9.39M
Shares
7.54M
Volume · Oct 20 279.51K Avg daily vol (3M) 4.52M

BIVI metrics

68 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.24
Market cap
$9.39M

Price action

20 metrics
Price change (1W)
+3.3%
Price change (30D)
-23.9%
Price change (3M)
-3.9%
Price change (6M)
-21.5%
Price change (YTD)
+6.9%
Price change (1Y)
-37.7%
Trailing year
Price change (5Y)
—
52-week high
$2.28
52-week low
$0.96
Change from 52-week high
-45.6%
Change from 52-week low
+28.6%
Annualized volatility
118.8%
Annualized volatility (3M)
182.8%
Beta
2.0
RSI (14D)
39.7
Price vs SMA 50
-24.7%
Price vs SMA 200
-18.2%
Avg volume (3M)
4.52M
Relative volume
0.1
Average dollar volume
$7.14M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
7.54M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.9
reciprocal yield 109.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-235.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-09-15

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$22.65M
Net income (TTM)
−$22.07M
Trailing 12 months
Diluted EPS (TTM)
$-3.05
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-4.49
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-4.32
Operating cash flow per diluted share (TTM)
$-5.14
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$2.18
Stock compensation per diluted share (TTM)
$0.47
Book value per share
$1.36

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
-163.8%
Shares change YoY
+307.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-214.9%
Return on assets
-154.9%
Debt / equity
0.0
Current ratio
3.6
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
3.6
Interest coverage
-1,265.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$8.98M
Latest balance sheet
Cash & equivalents
$8.98M
Total assets
$14.25M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$19.02M
Capital expenditures (TTM)
—
R&D (TTM)
$13.96M
SG&A (TTM)
$8.79M
Stock compensation (TTM)
$2.28M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
41
13F filer change QoQ
+1
Institutional ownership
51.1%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
7.7%
Private-fund adviser ownership
3.6%
Active holders' share change QoQ
-9.6%
Holder tenure
12.8
Price vs estimated holder cost
+23.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.9%

Short interest

3 metrics
Short interest
11.0%
Latest settlement · 2.7 days to cover
Days to cover
2.7d
Short-squeeze score
56 / 100

Insider activity

2 metrics
Net insider buying (90D)
$49,118
Insider-sentiment score
89 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1580149 CUSIP 09074F504 Visit website Investor relations